Anixa jumps as co's COVID-19 therapies could work against Delta variant

Anixa Biosciences

25/08/2021 14:13

** Biotech co's shares  ANIX.O  jump 14.1% to $5.19
premarket- set to open at over 5-mth high if gains hold
    ** Says a genomic variant analysis has indicated that its
potential COVID-19 therapy candidates may be even more effective
against the Delta variant than the original coronavirus
 urn:newsml:reuters.com:*:nPn4PJ5QZa
    ** ANIX, in collaboration with European partner MolGenie, is
identifying inhibitors of the main protease (Mpro), a key enzyme
involved in COVID-19
    ** Sequence analysis of several Delta variant samples
demonstrate that the Mpro enzyme often has a mutation,
indicating ANIX's candidates will be stronger inhibitors of the
variant than the original coronavirus- co
    ** ANIX had risen 48.2% YTD as of the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))